Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone for depression related to childhood trauma
NL-OMON52484Phase 2Completed
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mifepristone in major depressive disorder (MDD), sponsored by Vrije University Medical Center. Primary endpoint: Depressive symptom severity at 6 weeks. Started Dec 2021; status: completed.
02
Drugs
mifepristone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON52484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52484.